Ultragenyx Pharmaceutical Inc. (LON:0LIF)

Market Cap	1.97B
Revenue (ttm)	445.36M
Net Income (ttm)	-388.99M
Shares Out	n/a
EPS (ttm)	-4.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72
Average Volume	1,865
Open	28.41
Previous Close	27.08
Day's Range	27.94 - 28.41
52-Week Range	25.85 - 59.80
Beta	n/a
RSI	39.68
Earnings Date	Jul 31, 2025

About Acelyrin

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 1,294
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0LIF

Financial Performance

In 2024, Ultragenyx Pharmaceutical's revenue was $560.23 million, an increase of 29.01% compared to the previous year's $434.25 million. Losses were -$569.18 million, -6.17% less than in 2023.